A case report of anaphylaxis to Typhoid Vaccine Live Oral Ty21a (Vivotif)

Home  /  Publications  /  A case report of anaphylaxis to Typhoid Vaccine Live Oral Ty21a (Vivotif)

A case report of anaphylaxis to Typhoid Vaccine Live Oral Ty21a (Vivotif)

by admin May 17, 2017

AUTHORS

Haas NL, Haas MRC, Gregory C

ABSTRACT

Typhoid Vaccine Live Oral Ty21a (Vivotif) is typically well tolerated, and adverse events are infrequent and mild. To the best of the authors’ knowledge, only one prior anaphylactic reaction has previously been reported. We present a case of anaphylaxis related to Vivotif, in which a 66-year-old male with no medical comorbidities developed anaphylaxis following the third of a four-dose course (in the absence of concomitant vaccination administration), which consisted of tongue swelling, difficulty breathing, abdominal discomfort and rash. He was managed with epinephrine, corticosteroids and antihistamines.

Click here to view the article, published in Journal of Travel Medicine

Top